AATB Applauds Reintroduction of the Shandra Eisenga Human Cell and Tissue Product Safety Act

AATB commends Representatives John Moolenaar (R-MI) and Debbie Dingell (D-MI) for reintroducing the Shandra Eisenga Human Cell and Tissue Product Safety Act, a vital piece of legislation aimed at preventing tuberculosis (TB) infections linked to tissue transplants. If enacted, the bill will complement actions already taken by AATB to protect patients and ensure the highest standards of tissue safety, including AATB’s issuance and implementation of the Standards for Tissue Banking, 15th edition, which took effect on January 31, 2025.

The legislation includes important provisions to enhance healthcare practitioner knowledge of organ, tissue, and eye donation, and would promote evidence-based methods to approach patients and their families. Additionally, the bill would bring greater clarity to the Tissue Reference Group process at the Food and Drug Administration (FDA) that would provide much-needed guidance for tissue establishments. 

Earlier this week, AATB representatives visited Capitol Hill to advocate for key legislative priorities, including our support of the Shandra Eisenga Human Cell and Tissue Product Safety Act and the HCT/P Modernization Act of 2025. AATB looks forward to continued collaboration with Congress, the FDA, and industry stakeholders to drive this legislation forward and strengthen protections for patients and their families.

The text of the Shandra Eisenga Human Cell and Tissue Product Safety Act can be found here on Congressman Moolenaar’s website.